Logo do repositório
 
Publicação

Cardiovascular pharmacotherapy in 2025

2026-04-05Artigo de revisão Acesso aberto
Ver registo simples
datacite.subject.fosCiências Médicas::Ciências da Saúde
datacite.subject.sdg03:Saúde de Qualidade
dc.contributor.authorTamargo, Juan
dc.contributor.authorAgewall, Stefan
dc.contributor.authorAmbrosio, Giuseppe
dc.contributor.authorBorghi, Claudio
dc.contributor.authorCerbai, Elisabetta
dc.contributor.authorDan, Gheorghe A
dc.contributor.authorDrexel, Heinz
dc.contributor.authorFerdinandy, Péter
dc.contributor.authorGrove, Erik Lerkevang
dc.contributor.authorKlingenberg, Roland
dc.contributor.authorMorais, João
dc.contributor.authorParker, William
dc.contributor.authorRocca, Bianca
dc.contributor.authorSulzgruber, Patrick
dc.contributor.authorSemb, Anne Grete
dc.contributor.authorSossalla, Samuel
dc.contributor.authorKaski, Juan Carlos
dc.contributor.authorDobrev, Dobromir
dc.date.accessioned2026-09-09T13:43:21Z
dc.date.available2026-09-09T13:43:21Z
dc.date.issued2026-04-05
dc.descriptionA correction has been published: European Heart Journal - Cardiovascular Pharmacotherapy, Volume 12, Issue 3, May 2026, Page 231, https://doi.org/10.1093/ehjcvp/pvag028
dc.descriptionSupplementary material is available at European Heart Journal—Cardiovascular Pharmacotherapy online.
dc.description.abstractDespite recent advances in cardiovascular pharmacotherapy, prevention and treatment of many cardiovascular diseases remain limited with a clear need for more effective and safer pharmacological strategies. Here, we summarize the most relevant advances in cardiovascular pharmacotherapy in 2025, including the approval of four new drugs (aficamten, etripamil, lerodalcibep, and plozasiran), the label expansions for five already approved drugs, and the results of major randomized clinical trials with already approved drugs, including those that met the prespecified primary endpoints (positive trials) representing new pharmacological options for cardiovascular diseases, those with neutral or negative results, which did not confirm the primary endpoints and the withdrawal from the US market of Andexanet-alfa for safety concerns. Finally, we present the most promising experimental cardiovascular drugs currently being investigated in ongoing Phase 2 and 3 clinical trials.eng
dc.identifier.citationJuan Tamargo, Stefan Agewall, Giuseppe Ambrosio, Claudio Borghi, Elisabetta Cerbai, Gheorghe A Dan, Heinz Drexel, Péter Ferdinandy, Erik Lerkevang Grove, Roland Klingenberg, Joao Morais, William Parker, Bianca Rocca, Patrick Sulzgruber, Anne Grete Semb, Samuel Sossalla, Juan Carlos Kaski, Dobromir Dobrev, Cardiovascular pharmacotherapy in 2025, European Heart Journal - Cardiovascular Pharmacotherapy, Volume 12, Issue 3, May 2026, Pages 147–166, https://doi.org/10.1093/ehjcvp/pvag016
dc.identifier.doi10.1093/ehjcvp/pvag016
dc.identifier.eissn2055-6845
dc.identifier.issn2055-6837
dc.identifier.urihttp://hdl.handle.net/10400.8/16831
dc.language.isoeng
dc.peerreviewedyes
dc.publisherOxford University Press
dc.relation.hasversionhttps://academic.oup.com/ehjcvp/article/12/3/147/8586834
dc.relation.ispartofEuropean Heart Journal - Cardiovascular Pharmacotherapy
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectCardiovascular drugs
dc.subjectCardiovascular pharmacotherapy
dc.subjectPharmacological strategies
dc.titleCardiovascular pharmacotherapy in 2025eng
dc.typereview article
dspace.entity.typePublication
oaire.citation.endPage166
oaire.citation.issue3
oaire.citation.startPage147
oaire.citation.titleEuropean Heart Journal - Cardiovascular Pharmacotherapy
oaire.citation.volume12
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85
person.familyNameMorais
person.givenNameJoão
person.identifier.ciencia-id3614-652A-118E
person.identifier.orcid0000-0003-3406-2878
relation.isAuthorOfPublication3bc0f910-a460-461f-863a-1ca701ee597f
relation.isAuthorOfPublication.latestForDiscovery3bc0f910-a460-461f-863a-1ca701ee597f

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
Cardiovascular pharmacotherapy in 2025.pdf
Tamanho:
904.81 KB
Formato:
Adobe Portable Document Format
Ver/Abrir
Licença
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
license.txt
Tamanho:
1.32 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Ver/Abrir

Coleções

ciTechCare - Artigos
ESSLei - Artigos em revistas internacionais